MDB Capital HoldingsMDBH
MDBH
About: MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Employees: 40
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
60% more funds holding
Funds holding: 5 [Q3] → 8 (+3) [Q4]
11% more capital invested
Capital invested by funds: $1.08M [Q3] → $1.2M (+$116K) [Q4]
0.52% more ownership
Funds ownership: 3.32% [Q3] → 3.84% (+0.52%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MDBH.
Financial journalist opinion
Based on 3 articles about MDBH published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering
Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (Nasdaq: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will be joined by eXoZymes team members to ring the Nasdaq Stock Market (“Nasdaq”) closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024.
Neutral
GlobeNewsWire
1 week ago
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
Rebranding Invizyne Technologies, Inc to eXoZymes Inc. Changing NASDAQ ticker from IZTC to EXOZ Introducing but not trademarking “exozymes” as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of “EXOZ” effective before the market open. No action is required by existing shareholders with respect to the name and ticker symbol change.
Neutral
GlobeNewsWire
1 week ago
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025
Neutral
GlobeNewsWire
1 month ago
Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change
Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care.
Neutral
GlobeNewsWire
3 months ago
MDB Capital Holdings Provides Third Quarter 2024 Update
Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024. “Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB.
Neutral
GlobeNewsWire
3 months ago
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
Neutral
GlobeNewsWire
3 months ago
MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time
Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call.
Neutral
GlobeNewsWire
3 months ago
Invizyne Technologies Announces Closing of Initial Public Offering
Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol “IZTC” on November 13, 2024.
Neutral
GlobeNewsWire
3 months ago
Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology
Neutral
GlobeNewsWire
3 months ago
Invizyne Technologies Begins Trading on NASDAQ
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
Charts implemented using Lightweight Charts™